Following a couple of strategic developments, DiaMedica Therapeutics Inc.'s (NASDAQ: DMAC) shares are surging on US stock charts today. As of the most recent check, DMAC stock has gained 30.97% during the current-market session, reaching $2.96.
- Agreement Details
- Expanding Clinical Trial To Preeclampsia
Agreement Details
DiaMedica (DMAC) has signed definitive agreements to offer its common shares to accredited investors in a private placement. DMAC expects to receive $11.8 million in gross proceeds from this transaction. As per the conditions mentioned in the securities purchase agreements, DiaMedica will issue 4,720,000 common shares at a $2.50 per share purchase price.
The anticipated closing date of this private placement is June 28, 2024, subject to the satisfaction of normal closing requirements. The net proceeds of this private placement will be used to further DiaMedica's efforts related to product development and clinical research, particularly with regard to DM199.
This involves increasing clinical research on preeclampsia and sponsoring the crucial Phase 2/3 ReMEDy2 study for the treatment of acute ischemic stroke. The money will also go toward general business objectives and additional working capital, extending DiaMedica's financial runway until the third quarter of 2026.
Expanding Clinical Trial To Preeclampsia
Additionally, DiaMedica has disclosed that it intends to broaden clinical studies into preeclampsia, a hypertensive pregnancy disease for which there are no FDA-approved therapies and huge unmet medical needs. Preeclampsia is a potentially fatal illness that is marked by newly developed hypertension, proteinuria, and/or end organ malfunction. It poses serious dangers to both the mother and the unborn child.
As of right now, neither Europe nor the United States have authorized therapies for preeclampsia. Studies show that DM199 can successfully reduce blood pressure. DM199 is a big molecule protein that has been demonstrated in animal experiments to not penetrate the placental barrier, potentially providing a considerable safety advantage in illnesses associated to pregnancy, unlike small molecule anti-hypertensives, which are contraindicated.
With up to 120 participants and an expected cost of around $1.5 million, the preeclampsia study is planned to be very cost-efficient and provide a solid proof of concept for this indication.
在一些戰略性發展過後,Diamedica Therapeutics Inc. (納斯達克股票代碼:DMAC)的股票今天在美國股票交易圖表上大漲。截至最近一次檢查,DMAC股票在當天市場交易中上漲了30.97%,達到2.96美元。
協議詳情
DiaMedica(DMAC)已經簽署了關於向認可投資者提供普通股的最終協議。根據證券購買協議中的條件,DiaMedica將以每股2.5美元的價格發行4,720,000股普通股,DMAC預計將從此交易中獲得1180萬美元的總收益。
此次定向增發的預計截止日期爲2024年6月28日,取決於正常的交割要求得到滿足。此次私募股權的淨收益將用於進一步推動DiaMedica的產品開發和臨床研究,特別是與DM199有關的臨床研究。
這涉及到擴大早產子癇症的臨床研究,並贊助針對急性缺血性腦卒中治療的重要2/3階段ReMEDy2研究。這些資金還將用於一般業務目標和額外的運營資本,從而延長DiaMedica的財務行業,直至2026年第三季度。
擴大針對早產子癇症的臨床試驗
另外,DiaMedica還公開表示擬將臨床研究擴大到子癇症,這是一種沒有FDA批准的治療方法和巨大的醫療需求的高血壓妊娠疾病。子癇症是一種可能致命的疾病,新近發生的高血壓,蛋白尿,和(或)內部器官的功能障礙是此病的特點。它對母親和未出生的嬰兒都帶來嚴重的危險。
截至目前,歐洲和美國都沒有爲子癇症授權的療法。研究表明,DM199可以成功降低血壓。DM199是一種大分子蛋白質,動物實驗已經證明它不能穿過胎盤屏障,與小分子抗高血壓藥相比,這可能提供了相當大的安全優勢。
早產子癇症的研究計劃招募最多120名參與者,預計成本約爲150萬美元,這樣是非常高效的成本,併爲此指示提供了有力的概念證明。